COMMUNIQUÉS West-GlobeNewswire

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024
05/03/2024
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”) , an online global marketplace that connects scientists requiring biospecimens for medical research with [...]
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05/03/2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for [...]
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
05/03/2024
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: [...]
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
05/03/2024
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc [...]
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
05/03/2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with [...]
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
05/03/2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis WATERTOWN, Mass., March 05, 2024 [...]
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
05/03/2024
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical- [...]
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
05/03/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
05/03/2024
Nurix CSO Gwenn M. Hansen, Ph.D., invited as a featured presenter in two separate sessions focused on next-gen degraders and delivering degraders to the site of action SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- [...]
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
05/03/2024
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
iTeos présentera les données précliniques d’EOS-984, premier médicament de sa catégorie ciblant l’ENT1, lors de l'édition 2024 du congrès annuel de l’Association américaine pour la recherche sur le cancer
05/03/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 05 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
05/03/2024
SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of [...]
LifeScience Logistics Enhances Offerings with Innovative Sampling & Dispensing Suite at Raleigh-Durham Facility
05/03/2024
New cleanroom suite adds secure and compliant pharmaceutical sampling and dispensing offering to world-class pharmaceutical storage and distribution facility in Raleigh-Durham, North Carolina. DALLAS, March 05, 2024 ( [...]
Sandoz receives FDA approval for first and only denosumab biosimilars
05/03/2024
MEDIA RELEASE Wyost ® (denosumab-bddz) and Jubbonti ® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ® * (denosumab) and Prolia ® * (denosumab) FDA approval [...]
ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV
05/03/2024
LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced an oral presentation from its SLIM LIVER study (also known as A5371 [...]
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up
05/03/2024
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical [...]
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
05/03/2024
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
05/03/2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Places de cotation : [...]
AMN Healthcare Sustainability & Social Impact Report Shows Industry-Leading Efforts
05/03/2024
DALLAS, March 05, 2024 (GLOBE NEWSWIRE) -- In its recently released 2023 Sustainability and Social Impact Report , AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare [...]

Pages